NCT07700992Recruiting
A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
An Exosome-based and Machine-learning-powered Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 8 Jul 2026
- Start date
- 3 Jun 2026
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Università Vita-Salute San Raffaele
- Diseases
- Pancreatic cancer
- NCT number
- NCT07700992
What you commit to
- Study type: Observational
- Planned participants: 600
- From 3 Jun 2026 to the primary completion date, 31 Dec 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of pancreatic surgery or interventional procedures prior to plasma sample collection.
- Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.
Lab values
- Absence or insufficient quality/quantity of stored plasma samples for laboratory analysis.
Other
- Lack of clinical data required for cohort classification and/or outcome assessment.
- Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.
Who the study is looking for
- Adult men or women aged ≥18 years at the time of plasma sample collection.
- Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome
- Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).
- Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.
- Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.
- Prior provision of informed consent for biobanking and research use of biological samples and data
Age in the registry: 18 years to 99 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Hospital Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.